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ABSTRACT
Purpose: To report the 4-year outcomes of a consecutive series
of anal cancer patients treated with concurrent
chemo-radiation delivered with intensity-modulated
radiotherapy (IMRT), employing a simultaneous integrated
boost (SIB) approach.Methods: A consecutive series of 54
patients was enrolled between 2007 and 2013. Treatment
schedule consisted of 50.4 Gy/28 fractions (1.8 Gy daily) to the
gross tumor volume, while the elective nodal volumes were
prescribed 42 Gy/28 fractions (1.5 Gy/daily) for patients having
a cT2N0 disease. Patients with cT3-T4/N0-N3 tumors were
prescribed 54 (T3) or 60 (T4) Gy/30 fractions (1.8–2 Gy daily) to
the gross tumor volume; gross nodal volumes were prescribed
50.4 Gy/30 fr (1.68 Gy daily) if sized≤ 3 cm or 54 Gy/30 fr (1.8
Gy daily) if> 3 cm; elective nodal regions were given 45 Gy/30
fractions (1.5 Gy daily). Chemotherapy was administered
concurrently according to the Nigro’s regimen. Primary
endpoint was colostomy-free survival (CFS). Secondary
endpoints were local control (LC), disease-free survival (DFS),
cancer-specific survival (CSS), overall survival (OS), and toxicity
profile. Results:Median follow up was 32.6 months (range
12–84). The actuarial probability of being alive at 4 years
without a colostomy (CFS) was 68.9% (95% CI: 50.3%–84.7%).
Actuarial 4-year OS, CSS, DFS, and LC were 77.7% (95% CI:
60.7–88.1%), 81.5% (95% CI: 64%–91%), 65.5% (95% CI:
47.7%–78.5%), and 84.6% (95% CI: 71.6%–92%). Actuarial
4-year metastasis-free survival was 74.4% (95% CI:
55.5%–86.2%). Maximum detected acute toxicities were as
follows: dermatologic – G3: 13%; GI-G3: 8%; GU-G3: 2%;
anemia-G3: 2%; neutropenia-G3:11%; G4: 2%;
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thrombocytopenia- G3:2%. Four-year G2 chronic toxicity rates
were 2.5% (95% CI: 3.6–16.4) for GU, 14.4% (95% CI: 7.1–28) for
GI, 3.9% (95% CI: 1%–14.5%) for skin, and 4.2% (95% CI:
1.1–15.9) for genitalia. Conclusions: Our study shows the
feasibility of IMRT in the combinedmodality treatment of anal
cancer, with comparable results to the literature with respect to
LC, sphincter preservation and survival. Acute toxicity is lower
if compared to series employing standard techniques. Our
results support the use of IMRT on a routine basis for the
treatment of anal cancer.
Keywords: Anal cancer, IMRT, Concomitant radiochemotherapy,
Acute toxicity, Late toxicity, Radiotherapy, Radiation
INTRODUCTION
Up to the 80s, squamous cell carcinoma arising from the anal
canal has been treated with surgery consisting of abdomino-
perineal resection (APR) and permanent colostomy, with 5-
year overall survival (OS) rates in the range of 50%–70%,with
consistentmorbidities (impotence, potential abdominal wall,
and perineal fistulae) and eventual psychological and/or so-
cial issues associated to colostomy management (1). High-
dose external beam radiotherapy (EBRT) has been employed
as a sphincter saving alternative to surgery, with 3-years OS
rates of 75% as exclusive option (2). The integration of EBRT
and endocavitary brachytherapy (BRT) provides 5-year OS
rates > 65% with consistent sphincter function preserva-
tion (3). BRT alone achieves a 40%–50% local control (LC)
rate (3). Actually, combined modality treatment with con-
current chemo-radiation is considered as the standard of
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care in the management of anal cancer, providing consistent
OS rates (50%–78%), higher than with exclusive radiation,
and simultaneously sparing the anal sphincter with better
colostomy-free survival (CFS) rates (61%–76%) than surgical
approaches (4–6). Recently, updated results of the RTOG 98-
11 trial confirmed on a long-term basis combined EBRT and
concurrent 5-fluorouracil (5-FU) and mitomicin-C (MMC)
as the preferred treatment option, with 5-year disease-free
survival (DFS) and OS rates of 67.8% and 78.3%, respectively
(7). Nevertheless the same trial reported a high rate of ma-
jor acute toxicities (skin-G3/G4: 48%; gastrointestinal-G3-
G4: 35%),mainly due to the use of non-conformal techniques
such as AP/PA parallel opposed fields or 4-field conformal
approaches, covering a large amount of normal tissues and,
consequently, exposing organs at risk (OARs) to undue radi-
ation dose. Intensity-modulated radiotherapy (IMRT) is able
to provide robust conformality and modulation, abrupt dose
fall-off and reliable accuracy, also in the context of anal can-
cer, potentially reducing the dose to critical structures such
as bowel, bladder, genitalia, perineal skin, and bone mar-
row (8–11). We herein present a retrospective analysis of pa-
tients treatedwith concurrent IMRT and chemotherapy (CT)
within a consecutive case series.
MATERIALS AND METHODS
Eligibility Criteria
All patients accrued had a histologically confirmed diagno-
sis of anal cancer (anal canal or anal margin) characterized
as basaloid, keratinizing, and non-keratinizing and graded
according to the degree of differentiation. Patients were en-
rolled within three different Italian institutional hospitals
(University of Torino, Ivrea Community Hospital, and Aosta
Community Hospital). Tumor stage was defined according
to the 2002 American Joint Committee on Cancer indica-
tions and patients with clinical stage T1-T4, N0-N3 were en-
rolled. Other inclusion criteria included an Eastern Cooper-
ative Oncology Group (ECOG) performance status of 0–1,
age between 18 and 80, suitable hematological parameters
(neutrophils ≥ 1.5 × 109/l and platelets ≥ 100 × 109/l), ad-
equate renal and liver function. Exclusion criteria compre-
hended systemic disease at diagnosis, prior radiation to the
pelvic region, medical contraindications to chemo-radiation,
symptoms of bowel occlusion and/or gastro-intestinal bleed-
ing, malabsorption syndrome, peripheral neuropathy, psy-
chiatric disease hampering compliance to treatment, preg-
nancy, and breast-feeding. Written informed consent was
obtained for all patient. The Ethical Review Board of our
Institutional Hospitals approved the present study.
Pre-treatment Evaluation
Prior to accrual, all patients were evaluated by the gastro-
intestinal tumor board of our Institutions, made up of a ra-
diation oncologist, a medical oncologist, and an abdominal
surgeon. The clinical evaluation included complete medical
history with physical examination, comprising a digital rectal
examination and complete laboratory testing. Disease stag-
ing included a chest, abdomen, and pelvis computed tomog-
raphy scan (CT), a magnetic resonance imaging (MRI) of the
pelvic region, positron-emission tomography (PET) and/or
inguinal sentinel lymphnode biopsy (SLNB), and eventual
endoscopic transrectal ultrasounds (EUS) (12,13).
Radiotherapy
Patients underwent virtual simulation in supine position
with both an indexed shaped knee rest and ankle support
(CIVCO Medical Solutions, Kalona, IO, USA) in order to
prevent from hip rotation, but with no custom immobiliza-
tion. For planning purposes, a CT scan was performed and
3 mm slice thickness axial images were obtained from the
top of L1 vertebral body to the mid-femur. An isocenter was
found using the CT-simulation software Oncentra Master-
plan v. 3.0 (Nucletron, Veendhal, The Netherlands) within
the pelvic region and subsequently marked on the patient’s
skin under laser guidance for daily positioning. For contour-
ing purposes, the gross tumor volume (GTV) consisted of all
macroscopic foci of disease with respect to both primary tu-
mor and lymphnodes. GTV was defined taking into account
MRI and PET information after performing a non-rigid co-
registration within the Velocity software (Varian Medical
System, Palo Alto, CA, USA).
Those volumes were then isotropically expanded, adding
20 mm and 10 mm, respectively, to generate the correspond-
ing clinical target volumes (CTVs), but properly modified in
order to exclude surrounding osseous and muscular tissues.
The elective CTV encompassed the mesorectum and appro-
priate draining lymphatic regions such as inguinal, external
iliac, internal iliac, obturator, andperirectal nodes. For locally
advanced cases (cT4 and/or N2/N3), presacral nodes were
also included in the CTV. In general, lymphatic areas were
contoured as a 10 mm isotropic expansion around regional
vessels, with a subsequent modification to exclude bones and
muscles. A subsequent 10 mm isotropic margin was added
to generate the consequential planning target volume (PTV),
accounting for organ motion and set up errors (14,15). This
margin remained the same throughout the years in this co-
hort of patients for homogeneity, even if different strategies of
image-guidance were employed during those years (weekly
portal imaging for early and daily KvCT/MvCT for late pa-
tients). Dose prescription for target volumes was inspired by
Kachnic et al, being congruent to the clinical stage at presen-
tation (16). Basically, patients having a cT2N0 disease were
prescribed 50.4 Gy/28 fractions (1.8 Gy daily) to the gross
tumor PTV, while the elective nodal PTV was prescribed 42
Gy/28 fractions (1.5 Gy/daily). Patients with a cT3-T4/N0-
N3 disease were prescribed 54 (T3) or 60 (T4) Gy/30 frac-
tions (1.8–2 Gy daily) to the anal gross tumor PTV, while
gross nodal PTVs were prescribed 50.4 Gy/30 fr (1.68 Gy
daily) if sized≤ 3 cm or 54 Gy/30 fr (1.8 Gy daily) if> 3 cm;
elective nodal PTVwas prescribed 45Gy/30 fractions (1.5Gy
daily) (16). For inverse planning, target volumes objectives
were driven to obtain at least 95% of the prescribed dose to
95% of the PTV, 110% of prescription dose to ≤ 10% of the
PTV and ≤ 2% of PTV receiving < 95% of prescribed dose.
OARs dose constraints were adapted from Kachnic et al.
(14). Three different treatment modalities were available for
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patients: step and shoot (S&S) IMRT, volumetric arc-therapy
(VMAT), and helical tomotherapy (HT). For S&S IMRT,
plans were generated with up to seven modulated fields, em-
ploying 6 MV photons, depending on patients’ anatomy. For
VMAT, all plans were computed on ElektaMonaco treatment
planning system (version 3.2), allowing for optimizationwith
biological cost-functions for both PTV and OARs with hree
main functions (Poisson statistics cell-kill model, serial and
parallel complication models) and employing a single-arc of
360◦ (starting from 180◦) or, more recently, the dual-arc ap-
proach. Both S&S and VMAT plans were planned for Elekta
Synergy or Varian DHX-S LINACs. The XVMC/VEF Monte
Carlo algorithm with a 3% variance was used for all cases.
HT plans were generated using Tomotherapy Hi-Art version
4.1 (Accuray Inc, Sunnyvale, CA), choosing the appropri-
ate field width, pitch, and modulation factor and calculat-
ing the dose distribution of each beamlet with the convo-
lution/superposition algorithm. Generally, HT plans had a
modulation factor of 2.5–3.7, a pitch of 0.287 and a 2.5 cm
field width.
Chemotherapy
Patients received concomitant CT, consisting of 5-FU
(1,000 mg/m2/day) given as continuous infusion for 96 hr
(days 1–5 and 29–33) combined with MMC (10 mg/m2)
given as bolus (days 1 and 29). A total of two concurrent
cycles were planned for each patients. CT schedule adapta-
tion (for example mono-chemotherapy) was allowed based
on baseline patient’s characteristics. Blood cell counts were
routinely performed prior to each CT administration. Pro-
phylactic antiemetic medications consisted of intravenous
granisetron 3 mg and dexamethasone 8 mg. CT discontin-
uation or drugs modification were planned whenever G3-G4
toxicities according to NCI-CTC v3.0 occurred. Continua-
tion at reduced dose could be undertaken in case of toxic-
ity profile reduction down to G1. Patients were taken off the
study in case of persistence of toxicity ≥ G3 over 2 weeks or
repeated episodes of toxicity≥G3 occurring despite dose re-
duction.
Clinical Assessment
Acute gastro-intestinal (GI), genitourinary (GU), dermato-
logic, hematologic, genital, and osseous toxicities were as-
sessed during treatment and scored according to the Com-
mon Toxicity Criteria for Adverse Events scale v3.0. The
worst grade toxicity for each category observed within
90 days from treatment end was recorded as an acute toxicity
event. All toxicities occurring> 90 days from RT discontin-
uation were classified as late toxicity. During follow-up pa-
tients had a clinical examination with digital rectal exam and
anoscope observation at 4, 8, and 12 weeks. At 12 weeks, an
MRI was performed and bioptic sampling of the anal canal
was performed. A complete response was defined with re-
spect to the negativity of the pathology examination at biopsy.
A salvage APR was recommended for persistent disease (at
pathology) or for locally progressive or recurrent disease (at
imaging and pathology).
Table 1. Patients’ characteristics
Variable N (%)
Age
Mean 62
Range 39–78
Sex
Female 43(80)
Male 11(20)
HIV status
Positive 3(6)
Negative 51(94)
Primary tumor site
Anal canal 46(85)
Anal margin 7(13)
Both 1(2)
T stage
T1 1(2)
T2 33(62)
T3 17(31)
T4 3(5)
N stage
N0 30(55)
N1 7(13)
N2 14(26)
N3 3(6)
Global stage
II 29(54)
IIIA 8(15)
IIIB 17(31)
Grading
G1 17(31)
G2 18(33)
G3 19(36)
Preventive colostomy
Yes 5(10)
No 49(90)
Statistical Analysis
Disease recurrence was defined as local if occurring within
the anal canal and/or anal margin and/or mesorectum, re-
gional if involving draining lymphnodes (inguinal, external
iliac, internal iliac, obturator, perirectal, and presacral nodes)
and systemic if arising elsewhere. Local and regional failures
were taken into account for loco-regional control. Death of
disease was defined as death due to disease and taken into ac-
count for cancer-specific survival (CSS). Death of any cause
was considered for OS. All failures and cancer-related deaths
were considered forDFS.Death of any cause or submission to
definitive colostomy (excluding preventive colostomies)were
considered events for CFS. Failures in sites other than anal
region and draining lymphnodes were taken into account for
distant metastasis-free survival (DMFS). Survival curves and
actuarial rates of relapse were calculated using Kaplan–Meier
method. Multivariate analysis was performed using stepwise
Cox proportional hazard regression models and related to
OS, CSS, and DFS. A p value < 0.05 was considered sig-
nificant. Variables considered as continuous for the analy-
sis were: age, treatment breaks (days), overall treatment time
(OTT) (days), time between biopsy and radiotherapy start
(days). Variable considered as categorical were: sex, tumor
location (anal canal vs anal margin), stage, inguinal lymphn-
ode involvement, staging procedure (PET vs inguinal SLNB),
Copyright C© 2015 Informa Healthcare USA, Inc.
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Table 2. Treatment characteristics
Variable N (%)
IMRT approach
S&S 40 (74)
VMAT 7 (13)
Tomotherapy 7 (13)
PTV dose-tumor (Gy)
Mean 54
Range 50.4–60
PTV dose-positive nodes (Gy)
Mean 51.7
Range 50.4–54
PTV dose-negative nodes (Gy)
Mean 44
Range 42–45
Chemotherapy
5-FU + MMC 52 (96)
5-FU 1 (2)
MMC 1 (2)
Biopsy-RT interval (days)
Mean 72
Range 25–193
Chemotherapy dose reduction
Yes 14 (26)
No 40 (74)
RT duration (days)
Mean 44
Range 37–55
RT breaks ≥ 3 days
Yes 5 (9)
No 49 (91)
tumor grading, eventual CT dose reduction. Stata Statistical
Software, version 13.1 (Stata Corporation, Texas) was em-
ployed for analysis.
RESULTS
A total of 54 patients were enrolled from June 2007 to June
2013. For detailed patients characteristics see Table 1. Gen-
erally, patients had a mean age of 62 (range 39–78) and were
mainly female (80%), HIV-negative (94%), with an anal canal
primary (85%), T2-T3 stage (93%), N0-N2 (94%), G2-G3
(69%), and without a preventive colostomy (90%). Patients
weremainly treated with a S&S IMRT approach (74%).Mean
doses to the PTVs volumeswere 54Gy, 51.7Gy, and 44Gy for
the gross tumor, gross nodal, and elective nodal volumes, re-
spectively. Themean interval between biopsy andEBRT initi-
ation was 72 days.Mean EBRT duration was 44 days. Patients
undergoing a treatment break were 9 (17%) with a mean
duration of 3.9 days (considering also machine breakdown-
related ones). Those having breaks≥ 3 days were 9%. See Ta-
ble 2 for details.
Toxicity Profile
Acute toxicity for the whole cohort is presented in Table 3.
Maximum detected acute toxicities were as follows: derma-
tologic – G3: 13%; GI-G3: 8%; GU-G3: 2%; anemia-G3: 2%;
neutropenia-G3:11%; G4: 2%; thrombocytopenia- G3:2%.
Grade 3 events comprehended moist desquamation for skin
Table 3. Acute toxicity
N (%)
Acute toxicity G0 G1 G2 G3 G4
Skin 1(2) 9(16) 37(69) 7(13) 0
Gastrointestinal 10(18) 13(24) 27(50) 4(8) 0
Genitourinary 24(44) 12(22) 17(32) 1(2) 0
Anemia 50(93) 3(6) 1(2) 1(2) 0
Neutropenia 36(67) 2(4) 9(16) 6(11) 1(2)
Thrombocytopenia 48(88) 1(2) 4(8) 1(2) 0
toxicity, diarrhea with more than 7 stools per day for GI, and
cystitis interfering with activities of daily living for GU. Actu-
arial rates of main chronic toxicities may be seen in Figure 1;
in particular 4-year G2 chronic toxicity rates were 2.5% (95%
CI: 3.6–16.4) for GU, 14.4% (95% CI: 7.1–28) for GI, 3.9%
(95% CI: 1–14.5%) for skin, and 4.2% (95% CI: 1.1–15.9) for
genitalia. Grade 2 events consisted of colic pain and intermit-
tent intestinal bleeding, frequency and sporadic hematuria,
moderate atrophy to both perineal skin and external geni-
talia. A total of 14 out of 54 patients (26%) underwent a CT
dose reduction during treatment due to hematologic toxicity.
Clinical Outcomes
Median observation time was 32.6 months (range 12–84).
A total of 8 patients presented with a loco-regional fail-
ure. Three patients had persistent anal disease after com-
bined chemo-radiation; 4 patients experienced a local re-
lapse within the anal canal after treatment: among them 1
patient had a synchronous occurrence of both hepatic and
lung metastases and 1 a concomitant pelvic lymphnode fail-
ure. The remaining patient had a loco-regional failure within
pelvic nodes (with concurrent liver metastases). Six patients
received salvage APR; three patients had further CT and 1
patient underwent liver metastasis resection. A total of 10
patients developed distant metastases: 4 within the liver, 5
within the lungs, and 1 within both liver and lungs. Among
those, 3 patients had also loco-regional failure. All metastatic
patients received CT as part of their salvage treatment. Over-
all, 11 patients died; 8 of them were cancer-related deaths,
while 3 were due to other causes. Actuarial 4-year OS, CSS,
DFS, and LC were 77.7% (95% CI: 60.7%–88.1%), 81.5%
(95% CI: 64%–91%), 65.5% (95% CI: 47.7%–78.5%), and
84.6% (95% CI: 71.6%–92%) (see Figure 2). The actuarial
probability of being alive at 4 yearswithout a colostomy (CFS)
was 68.9% (95% CI: 50.3%–84.7%). Actuarial 4-year MFS
was 74.4% (95% CI: 55.5%–86.2%) (Figure 3).On multivari-
ate analysis, independent variables related to a worseOSwere
male sex (HR: 10.3; 95% CI: 1.2–89.6; p = 0.034), advanced
clinical stage (HR: 7.1; 95% CI: 1.3–39.7; p = 0.025), and
treatment breaks (HR: 1.5; 95% CI: 1.1–2.2). Inguinal node
involvement (HR: 28.6; 95% CI: 1.1–813; p = 0.05), clinical
stage (HR: 13.7; 95%CI: 1.6–116.1; p = 0.016), and treatment
breaks (HR: 2.2; 95% CI: 1.1–4.6; p = 0.023) also influenced
CSS in a statistically significant manner. Clinical stage (HR:
3.1; 95% CI: 1.2–8.5; p = 0.024) and treatment breaks (HR:
1.4; 95% CI: 1.04–1.75; p = 0.023) influenced also DFS.
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Figure 1. Chronic toxicity.
DISCUSSION
EBRT to the pelvic region for the treatment of anal can-
cer has been traditionally delivered with 2-dimensional or
3-dimensional approaches. Hence, a large amount of nor-
mal tissues was generally included within treatment fields,
leading to consistent unintended dose to critical structures
such as bladder, bowel, perineal region, and bone marrow
and consequently to high rates of acute toxicities and con-
sequential late effects (17). IMRT has been demonstrated to
Figure 2. Local control and survival.
Copyright C© 2015 Informa Healthcare USA, Inc.
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Figure 3. Sphincter preservation and systemic spread results.
provide a dosimetric advantage in terms of both target cover-
age and OARs avoidance compared to 3D-conformal EBRT
(18,19). Combined chemo-radiation in anal cancer patients
without the use of IMRT has been reported to have high
rate of GI (G3-G4: 35%, mainly diarrhea) and hematologic
(G3-G4: 61%) side effects, as shown in the RTOG 98-11 trial
(20). IMRT is able to provide a more favorable toxicity pro-
file. Salama et al. reported the use of intensity-modulated
EBRT as part of combined modality therapy within a multi-
institutional retrospective study, demonstrating a 15.1% rate
of G3 acute GI, 37% skin toxicities, and a 58.5% of G3-G4
hematologic side effects at 3 tertiary-care academic medical
centers(9). Interestingly, in this study all the Grade 4 events
were hematologic (leukopenia: 30.2%; neutropenia: 34%).
Treatment breaks occurred in 41.5% of patients, with a me-
dian duration time of 4 days (9). Kachnic et al. employed a
dose-painted IMRT approach, observing on a retrospective
multi-institutional framework, a G3 acute toxicity rate of 7%
for GI, 5% for GU, 5% for dermatologic, and 49% for hema-
tologic toxicities (13). In this series, G4 events were observed
not only for hematologic toxicity (12%), but also for GU (2%)
and dermatologic (5%). No G4 events were detected for GI.
Treatment breaks occurred in 40% of patients, with a me-
dian duration time of 2 days. Among them, patients with a
> 3 days break were 35% (16). Our results compared favor-
ably with reported series. In particular, G3 acute events were
13% for dermatologic toxicity, 8% forGI, 2% forGU, and 15%
for hematologic. Grade 4 events were seen only for neutrope-
nia (2%). Those rates are similar to those reported, excluding
for hematologic which was lower in our series, maybe due
to the fact that up to 26% of patients underwent a CT dose
reduction during combined modality treatment. Generally,
findings on early side effects were confirmed on a long-term
basis with a favorable chronic toxicity profile. In our cohort,
patients experiencing a treatment break were 9 (17%) with
a mean duration of 3.9 days. Those with a break ≥ 3 days
were 9%. The lower rate of acute toxicity in our study, with a
consequent acceptable rate and duration of treatment breaks
is notable, since overall treatment time is of paramount im-
portance in anal cancer. Patients enrolled in the RTOG 92-08
trial, which included amandatory 2-week break during treat-
ment, had a 30% 2-year colostomy rate, comparedwith a 10%
5-year colostomy rate in the RTOG 98-11 trial with patients
treated with 5-FU/MMC concurrent to EBRTwith no breaks
required (7, 21). In our series, all patients were treated with
an unconstrained IMRT approach towards pelvic bone mar-
row. Thus osseous structures were not included within the
optimization process as structures to be selectively avoided.
It has been demonstrated, in the context of both cervical and
anal cancer treated concomitantly to CT, that specific vol-
umes of pelvic bones receiving a certain dose have a signifi-
cant correlation with acute hematologic toxicity (10,22). On
multiple regression analysis, an increasing level of pelvic and
lumbosacral bone marrow receiving 5,10,15,20 Gy was sig-
nificantly associated with decreased white blood cell count
and absolute neutrophil count nadirs (10). Hence, a reduc-
tion in the rate, intensity, and duration of hematologic toxic-
ity may be hypothesized employing intentional sparing tech-
niques avoiding osseous structures with IMRT. In order to
prospectively test the hypothesis that intensity modulation
may potentially enlarge the therapeutic window, the RTOG
05-29 phase II trial investigated whether dose-painted IMRT
might be able to reduce by at least 15% the ≥ G2 GI and GU
toxicity rates, compared to conventional EBRT concurrent
to 5-FU/MMC as in the RTOG 98-11 trial (23). Although
the primary endpoint of the study was not reached, a sig-
nificant reduction in acute G2 hematologic (73% vs 85% for
RTOG 98-11), G3 GI (21% vs 36% for RTOG 98-11), and G3
dermatologic acute adverse events (23% vs 49% for RTOG
98-11) was observed (24). In the RTOG 05-29 study, over-
all treatment time was 43 days (range 32-59), comparably to
our cohort (44 days; range 37–55) and shorter than RTOG
98-11 (49 days; range 4–100). Treatment breaks were seen
in 49% of patients, higher than in our dataset (17%), but
lower than RTOG 98-11. Conversely, median interruption
time was lower than ours (median 0 days vs 3.9 days) and
RTOG98-11 (3 days). Actuarial 4-year rates of OS, CSS, DFS,
LCwere 77.7%, 81.5%, 65.5%, and 84.6%, respectively. More-
over, the actuarial probability of being alive at 4 years with-
out a colostomy (CFS) was 68.9%. Actuarial 4-year DMFS
was 74.4%. These results are similar to 5-year outcomes of
the EBRT/5-FU/MMC arm of RTOG98-11 (OS: 78.3%; DFS:
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67.8%; LC: 80%; CFS: 68.9%; DMFS: 86.9%), except for a
higher rate of distant metastases. Our findings support the
feasibility of IMRT in the combined modality treatment of
anal cancer. Clinical outcomes were comparable to those re-
ported in the literature, providing a proof of principle that,
generally speaking, IMRTmight not be detrimental in terms
of tumor control, anal sphincter preservation rate, and sur-
vival if compared to standard techniques. Acute skin toxic-
ity profile and consequently patient’s compliance seems im-
proved compared to historical data employing conventional
approaches (25). This may be due to the use of IMRT, but
also a role may be played by patients’ characteristics in our
cohort with themajority of patients having early tumors (T1-
T2: 64%; N0-N1: 68%), leading to the delivery of lower doses
to target volumes according to protocol strategy. In our se-
ries, several IMRT techniques have been used, including both
static (S&S) and volumetric/rotational (VMAT or tomother-
apy) approaches. This might be a potential selection bias,
given the different dosimetric outcomeswhichmay influence
toxicity profile. Since our series was not balanced in terms
of treatment techniques, with the majority of patients treated
with fixed gantry IMRT, and given that toxic event rate was
low, we were not able to perform a subset analysis account-
ing for technical aspects as variable. As a consequence, no
dosimetric factors could be investigated as predictors of toxi-
city. However, IMRT in our series seems to be reasonably safe
regardless of the approach employed. Treatment breaks are
decreased with respect to frequency and duration, compared
to historical series. This is important considering that in our
series, as in others, treatment breaks significantly worsened
DFS. In adjunct, we employed a SIB approach as in the RTOG
0529 trial, allowing for the delivery of a different daily dose to
selected treatment volumes during the same treatment frac-
tion. SIB has been demonstrated to provide dosimetric ben-
efits in terms of target volume dose conformity and homo-
geneity and normal tissue sparing in the setting of both head
and neck and breast cancer (26–28). This advantage may be
postulated also for anal cancer. This is of particular impor-
tance as the SIB approach is able to shorten the overall treat-
ment time with a consequent potential benefit on treatment
outcomes. With the treatment schedule we employed, SIB
leads us to deliver daily doses as low as 1.5 Gy to prophylactic
volumes. Given that only one local-regional relapse occurred
in negative-node regions irradiated with low daily dose, our
data seem to support the use of low dose per fraction for clin-
ically uninvolved regions as in RTOG 0529 trial and other
retrospective reports (23, 29). In general, our finding further
support the implementation and use of IMRT on a routine
basis for the treatment of cancer of the anal canal in combi-
nation with concurrent CT.
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